Our study has important translational implications and help to explain the functional impairment in T cells seen in trials of peptide vaccines in AML patients or more recently with CAR‐T cells.22 A more direct approach to metabolic modulating therapy would be to target the Arginase II enzyme's active site. This evidence concerns the gene ARG2 and acute myeloid leukemia.